Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 13/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21180352 | 0.81 | KLKB1 (0.33) | SMN1; SMN2KDM4EKMT2AKLKB1CSNK1D | |
| SCHEMBL21180353 | 0.81 | KLKB1 (0.33) | SMN1; SMN2KDM4EKMT2AKLKB1CSNK1D | |
| SCHEMBL21190208 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2KDM4EKLKB1MAP4K1MAPT | |
| SCHEMBL19780343 | 0.77 | KLKB1 (0.47) | KLKB1MAP4K1CYP3A4CYP2C9 | |
| SCHEMBL21190199 | 0.75 | KLKB1 (0.41) | KLKB1MAP4K1ALDH1A1 | |
| SCHEMBL21177153 | 0.75 | KLKB1 (0.43) | KMT2AKLKB1MAP4K1 | |
| SCHEMBL19779931 | 0.74 | KLKB1 (0.44) | KLKB1MAP4K1 | |
| SCHEMBL18371612 | 0.74 | CA2 (0.46) | KDM4EKMT2AKLKB1MAP4K1MAPT | |
| SCHEMBL19780021 | 0.74 | KLKB1 (0.46) | KLKB1MAP4K1 | |
| SCHEMBL19780636 | 0.73 | KLKB1 (0.47) | KLKB1MAP4K1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| US-10781200-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| WO-2019142053-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-07-25 | — | — | WO | disclosed |
| US-10301284-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-05-28 | — | — | US | disclosed |
| WO-2018011628-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SMN1; SMN2 4577/4885KDM4E 798/4885KMT2A 1049/4885 |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SMN1; SMN2 4577/4885KDM4E 798/4885KMT2A 1049/4885 |
| US-10781200-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SMN1; SMN2 4577/4885KDM4E 798/4885KMT2A 1049/4885 |
| US-10301284-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SMN1; SMN2 4577/4885KDM4E 798/4885KMT2A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.